Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M D'Incalci

Showing results (1-10 of 339) with videos related to

Pageof 34
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 1998
Differences in docetaxel and paclitaxel activity in resistant tumor cells which express MRP: need of comparative clinical trials in resistant patientsM D'Incalci
Current Opinion in Oncology|November 1, 1993
DNA-topoisomerase inhibitorsM D'Incalci
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 18, 1998
Some hope from marine natural productsM D'Incalci
European Journal of Cancer (Oxford, England : 1990)|February 2, 2002
One of the most interesting pro-apoptotic proteins recently identified is the TNF-related apoptosis-inducing ligand (TRAIL)M D'Incalci
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 1, 1994
First International Conference on Reversal of Multi-Drug Resistance, St. Gallen, 1-3 September 1994M D'Incalci
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 1, 1994
DNA-minor-groove alkylators, a new class of anticancer agentsM D'Incalci
Pharmacology & Therapeutics|January 1, 1987
Metabolism of triazine anticancer agentsM D'Incalci
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 10, 2010
Trabectedin in ovarian cancer: could we expect more?C Sessa, M D'Incalci
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1987
Podophyllotoxin derivatives VP-16 and VM-26M D'Incalci, S Garattini
Idrugs : the Investigational Drugs Journal|June 3, 2005
AACR-NCI-EORTC International conference--molecular targets and cancer therapeuticsM D'Incalci, G Damia
Pageof 34

Showing results (1-10 of 339) with videos related to

Sort By:
Pageof 34
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 1998
Differences in docetaxel and paclitaxel activity in resistant tumor cells which express MRP: need of comparative clinical trials in resistant patientsM D'Incalci
Current Opinion in Oncology|November 1, 1993
DNA-topoisomerase inhibitorsM D'Incalci
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 18, 1998
Some hope from marine natural productsM D'Incalci
European Journal of Cancer (Oxford, England : 1990)|February 2, 2002
One of the most interesting pro-apoptotic proteins recently identified is the TNF-related apoptosis-inducing ligand (TRAIL)M D'Incalci
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 1, 1994
First International Conference on Reversal of Multi-Drug Resistance, St. Gallen, 1-3 September 1994M D'Incalci
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 1, 1994
DNA-minor-groove alkylators, a new class of anticancer agentsM D'Incalci
Pharmacology & Therapeutics|January 1, 1987
Metabolism of triazine anticancer agentsM D'Incalci
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 10, 2010
Trabectedin in ovarian cancer: could we expect more?C Sessa, M D'Incalci
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1987
Podophyllotoxin derivatives VP-16 and VM-26M D'Incalci, S Garattini
Idrugs : the Investigational Drugs Journal|June 3, 2005
AACR-NCI-EORTC International conference--molecular targets and cancer therapeuticsM D'Incalci, G Damia
Pageof 34